Interactive Session:
190. Shots Across the Bow: Debates in Vaccinology
Saturday, October 6, 2018: 8:45 AM-10:00 AM
Room: N 24

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • explain the complexity of vaccine trials in pregnant women
  • discuss the impact of 3 versus 4 pneumococcal vaccines in children in the US
  • describe the known immune responses to repeated influenza vaccination

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Medical students and residents, Members-in-training, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Pediatric ID, Adult ID

Interactive Moderators:  H. Keipp Talbot, MD, MPH, Vanderbilt University Medical Center and Evan J. Anderson, MD, Atlanta Veterans Affairs Medical Center

Should Pregnant Women Be Included Early in Vaccine Clinical Trials?
8:45 AM
Carleigh Krubiner, PhD

8:57 AM
Phillip Heine, MD

Do We Really Need 4 Doses of PCV-13 in Children?
9:09 AM
Tamara Pilishvili, MPH, PhD
9:21 AM
Laura L. Hammitt, MD

Does Repeat Influenza Vaccination Reduce Vaccine Effectiveness?
9:33 AM
Edward Belongia, MD

9:45 AM
Robert L. Atmar, MD

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-261-L01-P


H. K. Talbot, Sanofi Pasteur: Investigator , Research grant . Gilead: Investigator , Research grant . MedImmune: Investigator , Research grant . Vaxinnate: Safety Board , none . Seqirus: Safety Board , none .

E. J. Anderson, NovaVax: Grant Investigator , Research grant . Pfizer: Grant Investigator , Research grant . AbbVie: Consultant , Consulting fee . MedImmune: Investigator , Research support . PaxVax: Investigator , Research support . Micron: Investigator , Research support .

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.